Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bleomycin + cyclophosphamide + dacarbazine + doxorubicin + etoposide + prednisone + rituximab + vinblastine + vincristine
- Development stage
- Preclinical
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination chemotherapy regimen containing multiple anticancer agents with different mechanisms of action. This combination includes monoclonal antibody therapy (rituximab), DNA-damaging agents (cyclophosphamide, doxorubicin, dacarbazine, bleomycin), antimitotic agents (vincristine, vinblastine), topoisomerase inhibitor (etoposide), and corticosteroid (prednisone). While this exact combination is not a standard named regimen, various subsets of these drugs are used in established regimens for treating lymphomas and other cancers.
02
Targets
CD20 (B-lymphocyte antigen CD20)TOP2A (DNA topoisomerase II)GR (Glucocorticoid receptor)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on bleomycin + cyclophosphamide + dacarbazine + doxorubicin + etoposide + prednisone + rituximab + vinblastine + vincristine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bleomycin + cyclophosphamide + dacarbazine + doxorubicin + etoposide + prednisone + rituximab + vinblastine + vincristine.